What Roche Diagnostics does

Roche Diagnostics Corporation is the North American headquarters of Roche's global diagnostics division, operating from Indianapolis since 1964 across 11 U.S. sites that include R&D centers in Pleasanton, San Jose, Santa Clara, Belmont, Wilmington, and Seattle, a manufacturing facility in Oro Valley, and additional operations in Carlsbad, Branchburg, and elsewhere. The company develops, manufactures, and distributes in vitro diagnostics products across five core laboratory segments: Core Lab (clinical chemistry, immunoassay, lab automation), Molecular Lab (cobas systems, LightCycler PCR, MagNA Pure extraction, syndromic testing), Pathology Lab (VENTANA IHC/ISH assays, BenchMark stainers, companion diagnostics, digital pathology), Point of Care (CoaguChek coagulation, Accu-Chek blood glucose, urinalysis, molecular POC), and Sequencing (KAPA NGS library prep, target enrichment, sequencing platforms). Its portfolio is anchored by proprietary platforms including cobas molecular systems (4800/5800/6800/8800), the Elecsys immunoassay family, VENTANA tissue diagnostics, and the PATHWAY anti-HER2/neu (4B5) companion diagnostic, with digital overlay through navify Portal and the mySugr diabetes management app.

The company serves clinical laboratories, hospitals, healthcare providers, pathology labs, and pharmaceutical partners across the United States. Its go-to-market is primarily enterprise field sales targeting healthcare providers and clinical laboratories, complemented by the navify Portal for digital ordering, technical documentation, and tracking, and laboratory partnerships for distributed channel reach. Revenue is generated through two primary streams: (1) hardware and consumables sales across the diagnostic platforms and instruments, with recurring reagent and assay revenue tied to installed instrument bases, and (2) digital solutions and services including navify Portal, Track and Trace, and connected diagnostic platforms. The company holds multiple FDA approvals and breakthrough device designations, including the first FDA-cleared Alzheimer's blood test (Elecsys pTau181), the first FDA-approved companion diagnostic for HER2-low and HER2-ultralow breast cancer, and one of the first FDA-approved HPV self-collection solutions.

Roche Diagnostics operates as a wholly-owned subsidiary of Roche Holding Ltd (SIX: RO/ROG; OTCQX: RHHBY), the Swiss multinational healthcare conglomerate, and is the legal entity for Roche's North American diagnostics operations. The business is supported by extensive regulatory compliance (HIPAA, GDPR, CCPA, FDA 21 CFR Part 11, California Health and Safety Code), and the parent company is the No. 1 R&D investor in healthcare with 13.2 billion CHF in annual R&D investment. Patient outcomes include 26.5 million women tested with Roche's HPV high-risk testing in 2024. The company is led by CEO Matt Sause and North America President and CEO Brad Moore, with senior leadership across Core Lab, Near Patient Care, Digital Pathology, and marketing functions.

Name

Roche Diagnostics

Legal name

Roche Diagnostics Corporation

Website

https://coaguchek.com

Company type

Private

Founded year

1964

Operating status

Operating

Short description

Roche Diagnostics Corporation is the North American diagnostics subsidiary of Roche Holding Ltd, developing and distributing laboratory, molecular, pathology, point-of-care, and sequencing diagnostic products for U.S. clinical laboratories, hospitals, and healthcare providers.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)

akta.pro secondary industry

Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB)

Keywords

• In vitro diagnostics
• Molecular diagnostics
• Clinical chemistry
• Tissue pathology diagnostics
• Point of care testing

Headquarters

HQ city

Indianapolis

HQ country

United States

HQ region

North America

Offices11 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Products and Instruments: Roche Diagnostics generates revenue through the sale of medical diagnostic tests, instruments, and platforms across multiple business areas including Core Lab, Point of Care, Molecular, and Pathology. Products include reagents, assays, and automated testing systems.
2. Digital Solutions and Services: Revenue from digital health tools, software platforms, and eServices including navify Portal, Track and Trace, and other connected diagnostic solutions.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Roche Diagnostics develops, manufactures, and distributes in vitro diagnostic products and automated testing instruments across core laboratory, molecular, pathology, point-of-care, and sequencing segments. The company sells reagents, assays, and instruments (cobas, Elecsys, VENTANA, LightCycler, MagNA Pure platforms) plus companion diagnostics and digital solutions such as navify Portal. Customers include clinical laboratories, hospitals, and healthcare providers for use in cancer, cardiac, infectious disease, women's health, and diabetes diagnostics.

Product overview

Roche Diagnostics offers a comprehensive in vitro diagnostics portfolio spanning multiple laboratory segments including Core Lab (clinical chemistry, immunoassay, mass spectrometry, lab automation), Molecular Lab (molecular diagnostics, syndromic testing, research solutions), Pathology Lab (IHC/ISH assays, automated staining, companion diagnostics, digital pathology), Point of Care (coagulation, blood glucose, urinalysis, molecular POC), and Sequencing (NGS library prep, target enrichment, sample prep automation, platforms, data analysis, assays). The portfolio includes both instrument platforms (cobas molecular systems, VENTANA BenchMark instruments, LightCycler PCR systems, MagNA Pure extraction) and assay products (HPV tests, Elecsys immunoassays, HER2 diagnostics, CINtec cytology/histology). Digital solutions include navify Portal for lab services, mySugr diabetes app, and Roche Digital Pathology Dx for whole slide imaging. Key brands include VENTANA, LightCycler, MagNA Pure, CoaguChek, Accu-Chek, mySugr, KAPA, and CustomBiotech. The company holds FDA approvals and clearances for numerous companion diagnostics including the first FDA-cleared Alzheimer's blood test (pTau181) and HER2-low/ultralow CDx.

Differentiator

Problem solved

Functional benefit

Brands

• navify®: Digital solutions platform for laboratory management and connectivity
• VENTANA®
• LightCycler®
• MagNA Pure®
• CoaguChek®
• Accu-Chek®
• mySugr®
• CustomBiotech
• KAPA

Products and services

• cobas 4800/5800/6800/8800 Systems Fully automated molecular diagnostic instrument platforms providing high-throughput testing. cobas 5800 offers up to 144 results in 8 hours, cobas 6800 provides 384 results, and cobas 8800 delivers 1,056 results per 8-hour shift. Used by clinical laboratories for HPV, viral load, and other molecular testing.
• cobas HPV Test Molecular test detecting 14 high-risk HPV genotypes including HPV 16, HPV 18, and 12 other pooled types. Used for primary cervical cancer screening and co-testing, running on cobas molecular instruments.
• Elecsys pTau181 blood test FDA-cleared Alzheimer's diagnostic blood test for primary care settings that helps rule out Alzheimer's disease in patients showing symptoms by measuring amyloid pathology markers on Elecsys platforms.
• Elecsys pTau217 assay Blood biomarker test for Alzheimer's disease developed in partnership with Eli Lilly. Received FDA breakthrough device designation to support earlier Alzheimer's diagnosis.
• Elecsys sFlt-1/PlGF ratio FDA-cleared preeclampsia risk assessment test using biomarkers sFlt-1 and PlGF. Provides 94.7% negative predictive value for predicting preeclampsia with severe features within two weeks. Available on cobas e platforms with results in under 18 minutes.
• CINtec PLUS Cytology
• CINtec Histology
• PATHWAY anti-HER2/neu (4B5)
• VENTANA BenchMark ULTRA PLUS Automated slide staining system for IHC and ISH testing in cancer diagnostics. Features redesigned packaging using 40% fewer raw materials for sustainability.
• Roche Digital Pathology Dx Whole slide imaging system for digital pathology. Demonstrated comparable to traditional microscopy for primary diagnosis in surgical pathology (AJCP study, June 2025).
• cobas connection modules (CCM) Vertical Automated laboratory conveyor system with vertical transportation for patient lab samples. Elevator and overhead components designed to optimize space, productivity, and patient care for low-, mid-, and high-volume laboratories.
• cobas connection modules (CCM)
• LightCycler PRO System Real-time PCR instrument for molecular diagnostics and research applications with virtual ecolabels providing environmental impact transparency.
• LightCycler Systems
• MagNA Pure Systems
• CoaguChek
• Accu-Chek
• mySugr
• navify Portal
• KAPA
• CustomBiotech
• HPV Self-Collection Solution FDA-approved human papillomavirus self-collection solution allowing women to privately collect their own vaginal sample for laboratory HPV testing.

Quantifiable outcome

• 26.5 million women tested with Roche HPV high-risk testing in 2024
• +3 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Partnerships

One partnership is on record.

• National Cancer Institute (NCI) / NIHcoreStrategic or Co-development Partner · 15 May 2024Roche collaborated with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), on the Cervical Cancer "Last Mile" Initiative. This public-private partnership facilitated the regulatory pathway towards FDA approval of Roche's HPV self-collection solution.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• bioMérieux: bioMérieux competes with Roche in molecular diagnostics (BioFire FilmArray syndromic panels), microbiology (VITEK), and industrial/applied diagnostics, with overlapping hospital lab customers and similar direct enterprise sales coverage.
• Cepheid (Danaher): Cepheid's GeneXpert rapid molecular systems compete directly with Roche's cobas molecular and LightCycler offerings, particularly in hospital point-of-care and decentralized molecular testing for infectious disease.
• Qiagen: Qiagen overlaps with Roche in sample preparation (MagNA Pure vs. QIAsymphony/QIAcube), molecular testing reagents, and NGS library preparation/KAPA-adjacent workflows for molecular diagnostic and research laboratories.
• Siemens Healthineers: Siemens Healthineers directly competes with Roche in Core Lab (Atellica CH/IM immunoassay and chemistry), molecular diagnostics, and laboratory automation, and is also a major IVD platform vendor to U.S. hospitals and integrated delivery networks.
• DiaSorin: DiaSorin competes with Roche's Elecsys immunoassay franchise in specialty testing (LIAISON XL), including infectious disease, vitamin D, and other specialty immunoassays sold to hospital and reference laboratories.
• Abbott Laboratories (Diagnostics): Abbott's Diagnostics segment competes head-to-head with Roche across immunoassay (Architect, Alinity ci-series), clinical chemistry, molecular (m2000, Alinity m), and point-of-care (i-STAT) with similar enterprise sales motion to hospital and reference labs in North America.
• Beckman Coulter (Danaher): Beckman Coulter offers DxI and Access immunoassay analyzers, DxH hematology, and clinical chemistry systems that directly overlap with Roche's Elecsys and cobas Core Lab portfolio, serving the same clinical laboratory customer base.
• Becton Dickinson (BD): BD's Diagnostic Systems and Life Sciences segments compete with Roche in molecular diagnostics (BD MAX system), clinical microbiology, and sample preparation for clinical laboratories and reference labs.
• Hologic: Hologic directly competes with Roche in women's health diagnostics (ThinPrep cytology, Aptima HPV/molecular) and Panther molecular systems, with strong overlap in cervical cancer screening where Roche's HPV self-collection and CINtec assays also play.
• Ortho Clinical Diagnostics: Ortho Clinical Diagnostics competes with Roche in high-volume clinical chemistry and immunoassay (Vitros systems) and in blood banking/immunohematology, serving overlapping hospital and blood bank customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/RocheDiaUSA
• YouTubeyoutube.com/user/RocheDiagnosticsUSA
• Facebookfacebook.com/RocheDiagnosticsUSA
• LinkedInlinkedin.com/showcase/roche-diagnostics-usa
• Instagraminstagram.com/rochediausa

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roche Diagnostics